10:07 AM EST, 03/03/2025 (MT Newswires) -- Roivant Sciences' ( ROIV ) subsidiary Genevant Sciences and Arbutus Biopharma ( ABUS ) said Monday they have filed five international lawsuits seeking to enforce patents protecting their lipid nanoparticle technology against infringement by Moderna ( MRNA ) and certain affiliates.

The enforcement actions target alleged infringing activities in 30 countries, the two companies said. They are seeking monetary relief and injunctions against Spikevax and, where applicable, additional Moderna ( MRNA ) products that allegedly use the same technology, including mRESVIA.

Lawsuits were filed in courts in Canada, Japan and Switzerland, while two were filed in the European Union's Unified Patent Court.

The enforcement actions expand on the two companies' ongoing enforcement proceeding in the US District Court for the District of Delaware, seeking fair compensation for Moderna's ( MRNA ) alleged infringement of six US patents in the manufacture and sale of Spikevax. A jury trial is currently scheduled for September, they said.

Moderna ( MRNA ) did not immediately respond to a request for comment from MT Newswires.

Price: 10.44, Change: -0.30, Percent Change: -2.79